Human Genetics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania, USA.
Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
BMJ Case Rep. 2024 Jan 4;17(1):e256155. doi: 10.1136/bcr-2023-256155.
The authors describe a female in her late twenties, presenting with catatonia and diagnosed with epilepsy, autism spectrum disorder, mild intellectual disability, psychosis, dysthymia, anxiety and bipolar disorder, receiving weekly electroconvulsive therapy (ECT). After testing, findings indicated an interstitial deletion in the 22q13.33 region associated with Phelan-McDermid syndrome. In addition, the patient had low cerebral spinal fluid tetrahydrobiopterin (BH) levels, suggesting dysfunction in the pterin biosynthetic pathway. As a result, the patient started on sapropterin, a BH replacement small molecule. After sapropterin treatment, catatonia improved, and the need for ECT decreased. There was an improvement in her cognitive ability, attention and independence. However, there has been no improvement in seizure frequency.
作者描述了一位 20 多岁的女性,表现为紧张症,被诊断为癫痫、自闭症谱系障碍、轻度智力障碍、精神病、心境恶劣、焦虑和双相情感障碍,每周接受电惊厥治疗(ECT)。检查后发现与 Phelan-McDermid 综合征相关的 22q13.33 区域的间质缺失。此外,患者脑脊液四氢生物蝶呤(BH)水平较低,提示蝶呤生物合成途径功能障碍。因此,患者开始使用 sapropterin,一种 BH 替代小分子。sapropterin 治疗后,紧张症得到改善,ECT 的需求减少。患者的认知能力、注意力和独立性都有所提高。然而,癫痫发作频率没有改善。